GlassScriptPhysician profile
Jonathan M Bridges
NPI 1598979973
$25,421.32
in general payments reported to CMS, 2019-2025
83 companies · $2,180 in 2025
The $2,180 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,130 · 2020: $3,765 · 2021: $4,074 · 2022: $4,404 · 2023: $4,487 · 2024: $2,381 · 2025: $2,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,365 · Long Term Medical Supply Or Device Loan: $583 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,365.11 |
| Long Term Medical Supply Or Device Loan | $583.31 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,772.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,791.04 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Mckesson Specialty Care Distribution, LLC | $1,410.07 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $1,346.28 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,159.58 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,119.93 | 2020-2025 | Gavreto, Rezlidhia, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $859.93 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Lilly USA, LLC | $842.99 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $828.21 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Eisai INC. | $737.35 | 2019-2025 | |
| Janssen Biotech, INC. | $706.59 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| US Oncology Corporate, INC. | $664.88 | 2022-2025 | |
| Amgen INC. | $631.87 | 2019-2023 | Kyprolis, Blincyto, Xgeva |
| Seagen INC. | $630.68 | 2019-2025 | Adcetris, Tukysa, Padcev |
| Abbvie INC. | $559.03 | 2019-2025 | Venclexta, Creon |
Show all 83 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $400.94 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Genzyme Corporation | $397.43 | 2019-2025 | |
| Incyte Corporation | $369.43 | 2020-2024 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $345.89 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $327.12 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $321.99 | 2019-2025 | |
| Kite Pharma, INC. | $320.02 | 2020-2024 | Yescarta |
| Alexion Pharmaceuticals, INC. | $301.24 | 2019-2023 | Ultomiris, Soliris |
| Myriad Genetic Laboratories, INC. | $298.68 | 2021-2024 | Bracanalysis Cdx, Precisetumor, Myrisk |
| Deciphera Pharmaceuticals INC. | $283.24 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Daiichi Sankyo INC. | $249.73 | 2019-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $238.52 | 2019-2023 | Iclusig, Fruzaqla, Vpriv |
| Pharmacyclics LLC, An Abbvie Company | $236.92 | 2019-2023 | Imbruvica |
| Csl Behring | $228.48 | 2019-2024 | Hizentra |
| Sobi, INC | $220.62 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $186.54 | 2019-2025 | Libtayo |
| Exelixis INC. | $179.38 | 2019-2025 | Cabometyx |
| Pharmaessentia USA Corporation | $173.26 | 2023-2025 | Besremi |
| Octapharma USA, INC. | $173.03 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $158.12 | 2021-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $131.60 | 2020-2023 | Xpovio |
| Coherus Oncology, INC. | $126.56 | 2024-2025 | Loqtorzi |
| Ucb, INC. | $125.00 | 2020 | |
| Stemline Therapeutics INC. | $124.08 | 2023-2025 | Orserdu |
| Onmark, INC. | $121.64 | 2023 | |
| Array Biopharma INC | $120.95 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Dova Pharmaceuticals | $120.24 | 2021 | |
| Beigene USA, INC. | $118.15 | 2021-2023 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.88 | 2020-2023 | Gilotrif |
| Cti Biopharma Corp. | $113.62 | 2022-2023 | Vonjo |
| Blueprint Medicines Corporation | $104.06 | 2020-2025 | Ayvakit |
| Puma Biotechnology, INC. | $101.51 | 2020-2025 | |
| Global Blood Therapeutics, INC. | $100.30 | 2020-2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Tesaro, INC. | $98.75 | 2019 | |
| Kyowa Kirin, INC. | $94.05 | 2019-2021 | |
| Astellas Pharma US INC | $80.83 | 2021-2024 | Xtandi, Xospata |
| Janssen Pharmaceuticals, INC | $77.60 | 2020-2021 | |
| Emd Serono, INC. | $66.69 | 2019-2023 | Bavencio |
| Jazz Pharmaceuticals INC. | $66.12 | 2020-2022 | |
| Taiho Oncology, INC. | $63.25 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $62.24 | 2023-2025 | Fotivda |
| Tempus Ai, INC | $53.85 | 2024 | |
| Morphosys, US INC. | $51.59 | 2021-2023 | Monjuvi |
| Myovant Sciences INC. | $50.93 | 2022 | |
| Immunogen, INC. | $45.89 | 2023-2024 | Elahere, Elahere |
| Ipsen Biopharmaceuticals, INC | $43.09 | 2021-2025 | Somatuline Depot, Onivyde |
| Hema Biologics, LLC | $42.14 | 2023 | Sevenfact |
| Acrotech Biopharma INC. | $37.69 | 2021-2023 | Beleodaq |
| Adaptive Biotechnologies Corporation | $34.77 | 2023 | Clonoseq |
| Apellis Pharmaceuticals, INC. | $31.57 | 2023 | Empaveli |
| Tersera Therapeutics LLC | $30.75 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $29.50 | 2020 | |
| Verastem, INC. | $29.47 | 2019 | |
| Spectrum Pharmaceuticals INC. | $22.33 | 2023 | Rolvedon |
| Beone Medicines USA, INC. | $21.90 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $18.81 | 2022 | |
| Agios Pharmaceuticals, INC. | $17.76 | 2023 | Pyrukynd |
| Springworks Therapeutics, INC. | $17.69 | 2025 | Ogsiveo |
| Shield Therapeutics INC | $17.62 | 2025 | |
| Sanofi-Aventis U.S. LLC | $16.65 | 2020 | |
| Mirati Therapeutics, INC. | $16.53 | 2023 | Krazati |
| Genmab U.S., INC. | $16.45 | 2023 | Epkinly |
| Tg Therapeutics, INC. | $15.40 | 2021 | |
| Partner Therapeutics, INC. | $13.92 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.75 | 2019 | |
| Mylan Institutional INC. | $13.48 | 2022 | |
| Progenics Pharmaceuticals, INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
Kisqali $798Lenvima $420Jaypirca $348Keytruda $348Verzenio $334Opdivo $254Imbruvica $229Qinlock $220Nubeqa $212Xofigo $212Venclexta $203Xtandi $192Reblozyl $176Besremi $173Pluvicto $170Trodelvy $169Hizentra $149Lynparza $146Opdualag $140Jakafi $134Imfinzi $129Enhertu $128Orserdu $124Inlyta $121Lutathera $117Jemperli $116Sarclisa $102Libtayo $102Scemblix $101Adcetris $99.16Epkinly $95.58Tecvayli $91.17Padcev $88.86Paxlovid $87.52Talzenna $86.67Romvimza $85.93Retevmo $84.71Cabometyx $83.84Monoferric $79.90Udenyca $79.08Bosulif $77.74Bavencio $77.39Orgovyx $76.36Oxbryta $75.79Darzalex $74.25Vonjo $71.58Tukysa $70.88Calquence $70.23Creon $67.62Comirnaty $64.35Welireg $64.03Talvey $62.97Brukinsa $62.35Fotivda $62.24Eliquis $59.72Columvi $58.59Polivy $58.59Lunsumio $58.59Doptelet $55.24Ayvakit $54.86Kyprolis $53.87Yescarta $52.78Bracanalysis Cdx $52.43Xpovio $51.53Fabhalta $49.84Krazati $48.49Ibrance $48.06Elrexfio $47.80Loqtorzi $47.48Iclusig $46.16Elahere $45.89Lorbrena $43.96Sevenfact $42.14Piqray $41.63Ojjaara $41.56Promacta $40.58Tgct $40.38Zejula $38.82Blincyto $38.15Tasigna $36.71Precisetumor $36.30Monjuvi $35.20Clonoseq $34.77Tecentriq $33.70Empaveli $31.57Somatuline Depot $31.38Onivyde $31.38Gilotrif $25.59Mekinist $24.41Braftovi $23.63Mektovi $23.63Rolvedon $22.33Wayrilz $22.29Beleodaq $22.28Pomalyst $22.04Erleada $21.56Ultomiris $20.77Nerlynx $20.75Elitek $20.60Xalkori $20.33
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bridges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.